Correlation Between Visfatin, Insulin Resistance (Homeostasis Model Assesment of Insulin Resistance), Inflammation (High Sensitivity C-Reactive Protein) and HDL Cholesterol Concentration in Individuals with Visceral Obesity

Rini Budiyati, Widjaja Lukito, Andi Wijaya

Abstract


BACKGROUND: Visfatin is a novel adipokine secreted from visceral adipose tissue and has insulinomimetic properties. Visceral obesity is a risk factor for metabolic syndrome. Insulin resistance and inflammation are linked to visceral obesity and metabolic syndrome. Dysregulation of visfatin as an adipokine could play an important role in metabolic syndrome through insulin resistance and inflammation, or lower HDL cholesterol concentration. However, this need more evidence.

METHOD: This was a crossectional study in 40 Indonesian obese men and 40 Indonesian obese women. Age: 30-60 years in men and 50-60 years for women, from February to March 2008 in Jakarta.

RESULTS: No correlation between visfatin and hs-CRP as a marker of inflammation (r=0.190, p=0,101), or HOMA-IR as a marker of insulin resistance (r=-0.020, p=0.246). Suprisingly visfatin concentration is correlated with HDL Cholesterol (r=0.416, p=0.000).

CONCLUSIONS: Visfatin plays an important role in metabolic syndrome through lipid metabolism. Positive correlation between visfatin and HDL cholesterol, was assumed that visfatin had a protective effect. Visfatin also known as as nicotinamide phosphoribosyltransferase (NAMPT) links Nicotinamide Adenine Dinucleotide (NAD) metabolism and raising of HDL Cholesterol. But the exact mechanisms need to be further studied.

KEYWORDS: visceral obesity, metabolic syndrome, NAMPT, visfatin, HDL


Full Text:

PDF

References


Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003; 112: 1785-8, CrossRef.

Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee M-J, et al. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab. 2007; 92: 666-72, CrossRef.

Rana JS, Nieuwdorp M, Jukema JW, Kestelein JJP. Cardiovascular metabolic syndrome – an interplay of obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab. 2007; 9: 218-32, CrossRef.

Eckell RH, Grundy SM, Zimmet,PZ. The metabolic syndrome. Lancet. 2005; 365: 1415-28, CrossRef.

Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Brit J Nutr. 2004; 92: 347. CrossRef.

Tanaka M, Nozaki M, Fukuhara A, Segawa K, Aoki N, Matsuda M, et al. Visfatin is released from 3T3-L1 adipocytes via a non classical pathway. Biochemical and Biophysical Research Communications. 2007; 359: 194-201, CrossRef.

Fukuhara A. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005; 307: 426-30, CrossRef.

Korner A, Garten A, Bluher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristic of serum visfatin and differential detection by immunoassay. J Clin Endrocinol Metab. 2007; 92: 4783-91, CrossRef.

Murphy KG, Bloom SR. Are all fats created equal? Nat Med. 2006; 12 : 32-3, CrossRef.

Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, Recasens M, Esteve E, Casamitjana R, et al. Serum visfatin increased with progressive β cell deterioraton. Diabetes. 2006; 55: 2871-5, CrossRef.

Bailey SD, Loredo-Osti JC, Lepage P, Faith J, Fontaine J, Desbiens KM, et al. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes. 2006; 55: 2896-902, CrossRef.

Markiewicz BZ, Glinianowicz MO, Janowska J, Kocełak P, Grabarczyk ES, Holecki M, et al. Serum concentration of visfatin in obese women. Metabolism. 2007; 56: 1131-4, CrossRef.

Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 2005; 54: 2911-6, CrossRef.

Sun G, Bishop J, Khalili S, Vasdev S, Gill V, Pace D, et al. Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men. Am J Clin Nutr. 2007; 85: 399-404, PMID.

Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clinical Endocrinology. 2007; 67: 796-800. CrossRef.

Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006; 91: 3165–70, CrossRef.

Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD Biosynthesis Enzyme. Cell Metab. 2007; 6 : 363-375, CrossRef.

Smith J, Al-Amri M, Sniderman A, Cianflone K. Visfatin concentration in Asian Indians is correlated with high density lipoprotein cholesterol and apolipoprotein A1. Clin Endocrinol. 2006; 65: 667–72, CrossRef.

Wang P, van Greevenbroek MMJ, Bouwman FG, Brouwers MCGJ, van der Kallen CJH, Smit E, et al. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Eur J Physiol. 2007; 454: 971–6, CrossRef.

Chen MP, Chung FM, Chang DM, Tsai JCR, Huang HF, Shin SJ, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006; 91: 295–9, CrossRef.




DOI: https://doi.org/10.18585/inabj.v2i1.111

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute